HER2+ Breast Cancer | Specialty

The Emerging Role of PI3K Inhibition in Breast Cancer

June 23rd 2016

The Ongoing Role of Everolimus in ER-Positive MBC

June 23rd 2016

FDA Breakthrough Status for Abemaciclib

June 23rd 2016

CDK4/6 Inhibitors in Hormone Receptor-Driven MBC

June 23rd 2016

ESR Mutations and Resistance to Endocrine Therapy in Breast Cancer

June 23rd 2016

Burris Discusses T-DM1 Update, Neoadjuvant Care in HER2+ Breast Cancer

June 23rd 2016

Howard A. "Skip" Burris, MD, offers insight on patient-reported outcomes from the MARIANNE trial and highlights exciting advancements in the neoadjuvant landscape of HER2-positive breast cancer.

Neoadjuvant HER2+ Breast Cancer Options Need Refinement, Expert Says

June 22nd 2016

Lisa A. Carey, MD, comments on the recent I-SPY 2 and KRISTINE findings, the I-SPY 2 program as a whole, and the work ahead in the neoadjuvant landscape of HER2-positive breast cancer.

Dr. Yardley on HERMIONE-2 Trial for HER2+ Breast Cancer

June 20th 2016

Denise A. Yardley, MD, senior investigator, Breast Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the phase II HERMIONE-2 trial, which is a randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician’s choice plus trastuzumab, in patients with anthracycline-naive HER2-positive, locally advanced/metastatic breast cancer who were previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1).

Biosimilar Era Gets Rolling in Oncology

June 17th 2016

After years of anticipation, biosimilar versions of the most widely administered monoclonal antibodies in oncology care are moving closer to fruition for the US market, starting with a new form of trastuzumab (Herceptin).

Biosimilar Trastuzumab Matches Herceptin in Efficacy and Safety

June 4th 2016

A biosimilar version of trastuzumab demonstrated equivalent efficacy and safety to the FDA-approved branded drug in a randomized phase III study among patients with HER2-positive metastatic breast cancer.

Lead NeoSphere Author Discusses Pertuzumab Update in HER2+ Breast Cancer

May 20th 2016

Luca Gianni, MD, discusses the significance of the long-term NeoSphere trial results and how the regimen is already impacting the landscape of HER2-positive breast cancer.

Expert Discusses Treatment Trends in HER2+ Breast Cancer

May 20th 2016

Sunil Verma, MD, discusses the current landscape in HER2-positive breast cancer and his views on neoadjuvant treatment options.

Long-Term Data Uphold Neoadjuvant Pertuzumab Benefit in HER2+ Breast Cancer

May 19th 2016

A 5-year follow-up of the phase II NeoSphere trial confirmed that patients with HER2-positive breast cancer receiving a 3-drug neoadjuvant pertuzumab regimen had better outcomes compared with patients receiving trastuzumab and docetaxel.

Dr. Hurvitz on Neoadjuvant Therapy for HER2+ Breast Cancer

May 11th 2016

Sara Hurvitz, MD, medical oncologist, General Internal Medicine, Hematology and Oncology at UCLA, discusses neoadjuvant treatment options for patients with HER2-positive breast cancer.

New Agents, Approaches Finding Place in Neoadjuvant HER2+ Breast Cancer

April 26th 2016

Sara Hurvitz, MD, discusses ongoing neoadjuvant studies in HER2-positive breast cancer, as well as what the future holds for neoadjuvant therapy.

Meredith Buxton on I-SPY 2 Trial for HER2+ Breast Cancer

April 26th 2016

Meredith Buxton, PhD, research director, assistant professor, University of California, San Francisco School of Medicine, discusses the I-SPY 2 trial for patients with HER2-positive breast cancer.

Neoadjuvant T-DM1/Pertuzumab Combo Boosts pCR in HER2+ Breast Cancer

April 25th 2016

Angela M. DeMichele, MD, explains the significance of the I-SPY 2 data, the advantages of T-DM1 versus standard of care, and what is on the horizon for the use of T-DM1 in HER2-positive disease.

Dr. DeMichele on the I-SPY2 Trial for HER2+ Breast Cancer

April 19th 2016

Angela M. DeMichele, MD, professor of Medicine and Epidemiology, University of Pennsylvania, discusses results of the HER2-positive breast cancer cohort of the phase II ISPY-2 trial, which investigated the neoadjuvant combinations of ado-trastuzumab emtansine (T-DM1) and pertuzumab (Perjeta) versus paclitaxel (Abraxane) and trastuzumab (Herceptin).

Neoadjuvant T-DM1 Plus Pertuzumab Shows Promise for HER2-Positive Breast Cancer

April 18th 2016

The combination of ado-trastuzumab emtansine and pertuzumab was superior to the combination of paclitaxel and trastuzumab as neoadjuvant treatment for women with HER2-positive breast cancer.

Early-Stage Therapies Rapidly Evolving in Breast Cancer

April 13th 2016

Early intervention has increasingly become the new standard of care for many patients with breast cancer, with an ever-growing collection of phase III trials currently exploring several novel or improved approaches.